Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 42.59
- Piotroski Score 3.00
- Grade Outperform
- Symbol (SLNO)
- Company Soleno Therapeutics, Inc.
- Price $54.10
- Changes Percentage (-2.84%)
- Change -$1.58
- Day Low $54.10
- Day High $56.01
- Year High $59.75
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/05/2025
- Fiscal Year End N/A
- Average Stock Price Target $73.00
- High Stock Price Target $93.00
- Low Stock Price Target $65.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.07
- Trailing P/E Ratio -22.01
- Forward P/E Ratio -22.01
- P/E Growth -22.01
- Net Income $-38,988,000
Income Statement
Quarterly
Annual
Latest News of SLNO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Soleno Therapeutics, Inc. (SLNO) Stock Price, News, Quote & History - Yahoo Finance
Soleno Therapeutics provides a regulatory update on DCCR for Prader-Willi Syndrome. FDA Review Division states no need for advisory committee meeting for the New Drug Application....
By Yahoo! Finance | 1 month ago
